Excipients Market Size & Growth Forecast 2026–2035, By Segments (Formulation, Product, Function), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Excipients Market size was valued at USD 10.53 Billion in 2025 and is anticipated to grow at a 4.1% CAGR from 2026 to 2035, surpassing USD 15.74 Billion by 2035. The industry revenue for 2026 is assessed at USD 10.9 billion.

• Base Year Value (2025): USD 10.53 Billion
• CAGR (2026-2035): 4.1%
• Forecast Year Value (2035): USD 15.74 Billion
• Historical Data Period: 2022-2025
• Largest Region: Europe
• Forecast Period: 2026-2035

Excipients Market Intelligence Snapshot:

• Regional Market Dynamics:

  • Europe held a 39.54% share in 2025 due to its mature pharmaceutical manufacturing sector, strong formulation expertise, and stringent quality standards supporting consistent demand for high-performance excipients.
  • Asia Pacific is projected to expand at a 4.67% CAGR as pharmaceutical manufacturing capacity increases, boosting demand for functional excipients that improve manufacturability, formulation stability, and drug delivery performance.

• Segment Momentum:

  • Oral formulations held a 58.26% share in 2025 because they dominate pharmaceutical manufacturing, relying on excipients for tablet binding, coating, stability, taste masking, and efficient large-scale production.
  • Alcohols are the fastest-growing product segment as their roles in improving solubility, preservation, and processing efficiency support increasing use in liquid and semi-solid pharmaceutical formulations.

• Market Expansion Drivers:

  • Rising demand for advanced drug formulations enhancing stability and bioavailability of therapies.
  • Growth in biologics and targeted drug delivery systems increasing demand for functional excipients.
  • Expansion of nanoparticle-based and sustained-release formulations driving excipient innovation.

• Leading Market Participants:

  Top players in the excipients market include BASF SE (Germany), Ashland Inc. (United States), Roquette Frères S.A. (France), Colorcon Inc. (United States), Eastman Chemical Company (United States), The Lubrizol Corporation (United States), FMC Corporation (United States), Avantor, Inc. (United States), Evonik Industries AG (Germany), DuPont de Nemours, Inc. (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 10.53 Billion
  • Projected Market Size: USD 15.74 Billion by 2035
  • Growth Forecasts: 4.1% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: Europe
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Oral (Formulation) | Polymers (Product) | Binders (Function)
  • Emerging Opportunity Segment: Topical (Formulation) | Alcohols (Product) | Lubricants and Glidants (Function)

Market Growth Drivers and Industry Trends

Rising demand for advanced drug formulations enhancing stability and bioavailability of therapies

As drug developers work with more complex active ingredients, formulation performance has become a central purchasing criterion, pushing the excipients market toward materials that do more than provide bulk or basic processing support. Poor solubility, moisture sensitivity, and variable absorption increasingly require excipients that can stabilize APIs, improve dissolution, control release behavior, and protect therapeutic efficacy through manufacturing and shelf life. This is driving demand for the excipients market toward multifunctional polymers, lipids, sugars, and co-processed systems that help manufacturers reduce formulation risk and accelerate development decisions, especially where improved bioavailability can determine whether a therapy advances commercially.

Growth in biologics and targeted drug delivery systems increasing demand for functional excipients

The rise of biologics and precision delivery approaches is reshaping formulation priorities, since these therapies are often highly sensitive to temperature, shear, aggregation, and chemical degradation. In the excipients market, that is increasing market penetration for high-purity, specialized excipients used to maintain protein stability, support injectability, enable site-specific delivery, and preserve performance during storage and administration. Procurement and formulation teams are placing greater emphasis on excipient functionality, consistency, and regulatory documentation, which strengthens market development for suppliers capable of meeting the technical and quality requirements associated with complex biologic products and targeted delivery platforms.

Expansion of nanoparticle-based and sustained-release formulations driving excipient innovation

Nanoparticle systems and sustained-release dosage forms depend heavily on excipient architecture, making excipient selection a core part of product design rather than a downstream manufacturing choice. In the excipients market, this is supporting market expansion for materials that can control particle size, surface behavior, encapsulation efficiency, and release kinetics, particularly in formulations where therapeutic performance is tied directly to delivery precision. The result is a shift toward tailored carrier systems, surface modifiers, and matrix-forming excipients, as pharmaceutical companies seek formulation partners that can help translate advanced delivery concepts into scalable, reproducible products.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising demand for pharmaceutical and food excipients	1.30%	Short term (≤ 2 yrs)	North America, Europe	Medium	Fast
Innovations in excipient formulations	1.40%	Medium term (2–5 yrs)	North America, Asia Pacific	Low	Moderate
Expansion of production capacity in emerging markets	1.40%	Long term (5+ yrs)	Asia Pacific, Latin America	Low	Slow
Rising demand for advanced drug formulations enhancing stability and bioavailability of therapies	2.20%	High	North America, Europe	High	Near Term
Growth in biologics and targeted drug delivery systems increasing demand for functional excipients	2.00%	High	North America, Asia Pacific	High	Mid Term
Expansion of nanoparticle-based and sustained-release formulations driving excipient innovation	1.60%	Moderate	Europe, Asia Pacific	Emerging	Long Term

Regional Demand Dynamics

Europe (Largest Region) vs Asia Pacific (Fastest-Growing Region)

Europe held a 39.54% share of the excipients market in 2025, supported by its mature pharmaceutical manufacturing base, established formulation expertise, and stringent quality and regulatory standards that sustain demand for high-performance excipient materials. The region’s leadership is strengthened by the concentration of drug manufacturers that require consistent, compliant inputs for solid oral, injectable, and specialty formulations, which keeps procurement volumes stable and supports ongoing product use across both innovator and generic production environments.

Asia Pacific is projected to expand at a 4.67% CAGR over the forecast period, with growth in the excipients market being propelled by the continued expansion of pharmaceutical manufacturing capacity and rising formulation activity across cost-competitive production hubs. Demand is accelerating as more drug makers scale output for domestic consumption and export supply, increasing the need for a broader range of functional excipients that improve manufacturability, stability, and delivery performance in high-volume production settings.

Key Country Insights

United States

Advanced Formulation Support

The U.S. excipients market is driven by pharmaceutical innovation and increasing demand for complex drug formulations. Manufacturers are developing multifunctional excipients that improve drug stability, manufacturability, and delivery performance while meeting stringent quality expectations.

Japan

High-Purity Ingredient Focus

Japan emphasizes premium excipients designed for formulation consistency and pharmaceutical quality assurance. Companies continue investing in specialized materials that enhance dosage accuracy and support advanced drug development programs.

South Korea

Biopharma Production Support

South Korea's excipients market is expanding alongside pharmaceutical manufacturing and biopharmaceutical development. Demand is increasing for functional excipients that improve production efficiency while supporting innovative dosage forms and therapeutic applications.

Germany

Quality Manufacturing Standards

Germany prioritizes high-quality pharmaceutical excipients that support precision manufacturing and regulatory compliance. Suppliers focus on consistent material performance and robust quality systems to serve both innovative and established drug manufacturers.

France

Specialized Pharmaceutical Inputs

France maintains steady demand for pharmaceutical excipients that enable sophisticated drug formulations and manufacturing reliability. Producers are prioritizing customized ingredient solutions that align with evolving pharmaceutical quality and regulatory requirements.

Italy

Generic Medicine Formulations

Italy relies on high-quality excipients to support generic pharmaceuticals and contract manufacturing activities. Manufacturers are adopting versatile excipient portfolios that improve formulation efficiency while maintaining consistent product performance.

Segment Leadership and Growth Trends

  Formulation Segment Analysis: Oral (Largest Segment) vs Topical (Fastest-Growing Segment)

Within the excipients market, Oral formulation held the leading position in 2025 with a 58.26% share, reflecting its entrenched role across high-volume solid and liquid drug delivery formats. This leadership is maintained through the broad manufacturing base for oral pharmaceuticals, where excipients are essential for tablet binding, disintegration, coating, taste masking, and stability control. The Oral segment also benefits from established production workflows and widespread patient acceptance, which keep demand concentrated in formulations that can be efficiently scaled and distributed.

Topical formulation is emerging as the fastest-growing segment in the excipients market as drug developers place greater emphasis on localized delivery, skin-compatible performance, and differentiated patient-friendly dosage forms. Growth is being aided by the need for excipients that improve spreadability, absorption behavior, texture, and formulation stability in creams, gels, and ointments. Compared with oral formats, topical products are gaining momentum where targeted application and non-invasive administration better match evolving therapeutic and consumer use requirements.

Product Segment Analysis: Polymers (Largest Segment) vs Alcohols (Fastest-Growing Segment)

Polymers accounted for the largest position in the excipients market in 2025, holding a 48.43% share as their functional versatility keeps them central to a wide range of pharmaceutical formulations. Their leadership is rooted in practical formulation needs, since polymers are widely used to control drug release, improve viscosity, support film coating, and enhance product stability across multiple dosage forms. This broad utility makes them a dependable base material for manufacturers seeking consistent processing performance and formulation adaptability.

Alcohols are the fastest-growing product segment in the excipients market, driven by their expanding use in formulations where solubility enhancement, preservation support, and processing efficiency are critical. Their momentum is strongest in applications that require effective solvent behavior or formulation assistance in liquid and semi-solid systems, giving them an advantage over alternatives with narrower functional roles. As pharmaceutical development increasingly targets more specialized delivery formats, alcohols are seeing faster uptake because they address immediate formulation and manufacturability challenges.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Formulation	Oral, Topical, Parenteral, Others	Oral	Topical
Product	Polymers, Alcohols, Sugar, Minerals, Gelatin	Polymers	Alcohols
Function	Fillers and Diluents, Suspending & Viscosity Agents, Coating Agents, Binders, Flavoring Agents & Sweeteners, Disintegrants, Colorants, Lubricants and Glidants, Preservatives, Emulsifying Agents, Others	Binders	Lubricants and Glidants

Competitive Landscape and Market Positioning

Major players in the excipients market:

1. BASF SE (Germany)

2. Ashland Inc. (United States)

3. Roquette Frères S.A. (France)

4. Colorcon Inc. (United States)

5. Eastman Chemical Company (United States)

6. The Lubrizol Corporation (United States)

7. FMC Corporation (United States)

8. Avantor Inc. (United States)

9. Evonik Industries AG (Germany)

10. DuPont de Nemours Inc. (United States)

The excipients market is advancing due to increasing demand for improved drug formulation efficiency and stability. Continuous innovation in formulation science is enhancing drug delivery performance. Collaborative research initiatives are supporting development of specialized excipient systems, while new product introductions are addressing complex pharmaceutical requirements. These developments are strengthening competitiveness in the excipients market.

Industry Development/News

Company Name	Date	Key Development
Ingredion	May-26	Ingredion entered a strategic partnership with Sanstar Limited, involving a preferential equity investment and a joint venture agreement. The collaboration aims to scale production of specialty pharmaceutical excipients in India, combining local manufacturing expertise with global innovation resources to bolster supply chain capacity and market penetration in the region.
Safic-Alcan	May-26	Safic-Alcan acquired a majority stake in S.A. Ingredients Private Limited to expand its specialty chemicals and excipients distribution footprint in India. This acquisition strengthens its regional supply chain and enhances service delivery for pharmaceutical customers, supporting growth across India’s rapidly expanding life sciences and formulation sectors.
Clariant	Mar-26	Clariant opened a GMP-compliant polyethylene glycol (PEG) production facility at its Clear Lake, Texas site. As the company’s first US-based excipient manufacturing plant, this investment aims to enhance supply chain resilience and provide reliable access to high-quality, regulated excipients for pharmaceutical manufacturers across North and Latin America.
Univar Solutions	Mar-26	Univar Solutions was appointed as a distributor for Ingredion Pharma Solutions across the United States and Canada. This partnership expands Univar’s pharmaceutical excipient portfolio, improving regional access to specialty ingredients and enhancing supply chain efficiency for pharmaceutical formulation customers throughout the North American market.
Roquette	May-25	Roquette completed the acquisition of IFF Pharma Solutions, significantly strengthening its global excipient portfolio and drug delivery capabilities. The integration consolidates advanced formulation expertise and broadens the company's product offerings, reinforcing its strategic position as a primary partner for pharmaceutical manufacturers seeking innovative drug delivery solutions.
Daesang	Dec-25	Daesang acquired German amino acid manufacturer Amino GmbH to facilitate entry into the pharmaceutical and biotechnology ingredients sector. The acquisition expands Daesang’s excipient-related portfolio and supports its corporate strategy to diversify into high-value life sciences markets through specialized amino acid-based formulation technologies.
Nitika Pharmaceutical Specialties	Jun-25	The Technology Development Board granted financial support to Nitika Pharmaceutical Specialties under India’s PLI scheme. The funding is dedicated to scaling domestic manufacturing of 14 advanced excipients, a strategic effort to enhance local production capacity and reduce reliance on imported ingredients within the pharmaceutical supply chain.
BASF	Jun-25	BASF inaugurated a GMP Solution Centre in Michigan to provide specialized support for pharmaceutical and biopharmaceutical formulation. By localizing advanced excipient technical support and bioprocessing services, the facility enhances BASF’s regional supply reliability and strengthens its competitive positioning within the North American pharmaceutical market.
JRS Pharma	Jul-24	JRS Pharma and Gujarat Microwax established a new pharmaceutical excipient manufacturing facility in Mehsana, India. The project increases regional production capacity for specialty ingredients, addressing the growing demand for high-quality excipients and strengthening the regional supply chain for pharmaceutical manufacturing in the Indian market.
IMCD	Jan-24	The Competition Commission of India approved IMCD India’s acquisition of an additional 30% stake in Signet Excipients. This transaction deepens IMCD’s control over its excipient distribution business, improving its capability to market and supply pharmaceutical ingredients throughout India’s formulation supply chain.